(Hypertension. 1995;26:131-136.)
© 1995 American Heart Association, Inc.
Articles |
Transient Decrease in High Blood Pressure by In Vivo Transfer of Antisense Oligodeoxynucleotides Against Rat Angiotensinogen
From the Department of Geriatric Medicine, Osaka (Japan) University Medical School (N.T., R.M., J.H., M.A., Y.N., H.M., T.O.); Institute for Molecular and Cellular Biology, Osaka University (Y.K.); and Department of Applied Biochemistry, University of Tsukuba, Ibaraki, Japan (A.F., K.M.).
Correspondence to Toshio Ogihara, MD, Department of Geriatric Medicine, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565, Japan.
Abstract The renin-angiotensin system plays an important role in blood pressure regulation. Angiotensinogen, which is mainly produced in the liver, is a unique component of the renin-angiotensin system, because angiotensinogen is only known as a substrate for angiotensin I generation. It is unclear whether circulating angiotensinogen is a rate-limiting step in blood pressure regulation. Recent findings of genetic studies and analyses suggest that the angiotensinogen gene may be a candidate as a determinant of hypertension. To test the hypothesis that angiotensinogen may modulate blood pressure, we transfected antisense oligonucleotides against rat angiotensinogen into the rat liver via the portal vein using liposomes that contain viral agglutinins to promote fusion with target cells, a technique that has been reported to be highly efficient. Transfection of antisense oligonucleotides resulted in a transient decrease in plasma angiotensinogen levels in spontaneously hypertensive rats from day 1 to day 7 after the injection, consistent with the reduction of hepatic angiotensinogen mRNA. Plasma angiotensin II concentration was also decreased in rats transfected with antisense oligonucleotides. Moreover, a transient decrease in blood pressure from day 1 to day 4 was observed, whereas transfection of sense and scrambled oligonucleotides did not result in any changes in plasma angiotensinogen level, blood pressure, or angiotensinogen mRNA level. Overall, our results demonstrate that transfection of antisense oligonucleotides against rat angiotensinogen resulted in a transient decrease in the high blood pressure of spontaneously hypertensive rats, accompanied by a decrease in angiotensinogen and angiotensin II levels. These findings suggest that angiotensin production may be directly proportional to circulating angiotensinogen concentration and also raise the possibility that angiotensinogen may be a potential target for antihypertensive drugs.
Key Words: oligonucleotides, antisense • parainfluenza virus type I • hypertension, genetic • rats, inbred SHR • gene therapy
This article has been cited by other articles:
 |
|
 |
|
  M. K. Raizada and S. D. Sarkissian Potential of Gene Therapy Strategy for the Treatment of Hypertension Hypertension, January 1, 2006; 47(1): 6 - 9. [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. R. Klett, D. Anderson, M. Sholook, and J. P. Granger Antisense oligodeoxynucleotides directed against a novel angiotensinogen mRNA-stabilizing protein reduce blood pressure in spontaneously hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2004; 287(3): R619 - R626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. R. Klett and J. P. Granger Physiological elevation in plasma angiotensinogen increases blood pressure Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1437 - R1441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Phillips Gene Therapy for Hypertension: The Preclinical Data Hypertension, September 1, 2001; 38(3): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ishikawa, S. Baba, T. Katsuya, N. Iwai, T. Asai, M. Fukuda, S. Takiuchi, Y. Fu, T. Mannami, J. Ogata, et al. T+31C Polymorphism of Angiotensinogen Gene and Essential Hypertension Hypertension, February 1, 2001; 37(2): 281 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Garcia, A. L. Alvarez, P. I. Porto, V. M. Garfunkel, S. Finkielman, and C. J. Pirola Antisense Inhibition of Thyrotropin-Releasing Hormone Reduces Arterial Blood Pressure in Spontaneously Hypertensive Rats Hypertension, February 1, 2001; 37(2): 365 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Gelband, M. J. Katovich, and M. K. Raizada Current Perspectives on the Use of Gene Therapy for Hypertension Circ. Res., December 8, 2000; 87(12): 1118 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gardon, M. K Raizada, M. J Katovich, K. H Berecek, and C. H Gelband Gene therapy for hypertension and restenosis Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 211 - 216. [PDF]
|
|
|
|
 |
|
 N. TOMITA, R. MORISHITA, H. Y. LAN, K. YAMAMOTO, M. HASHIZUME, M. NOTAKE, K. TOYOSAWA, B. FUJITANI, W. MU, D. J. NIKOLIC-PATERSON, et al. In Vivo Administration of a Nuclear Transcription Factor-{kappa}B Decoy Suppresses Experimental Crescentic Glomerulonephritis J. Am. Soc. Nephrol., July 1, 2000; 11(7): 1244 - 1252. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Tomita, H. Takano, N. Tomita, R. Morishita, M. Kaneko, K. Shi, K. Takahi, T. Nakase, Y. Kaneda, H. Yoshikawa, et al. Transcription factor decoy for NF{kappa}B inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis Rheumatology, July 1, 2000; 39(7): 749 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.-J. Moon, K. Choi, Y.-K. Choi, J.-E. Kim, Y. Lee, A. D. Schreiber, and J.-G. Park Potent Growth Inhibition of Leukemic Cells by Novel Ribbon-type Antisense Oligonucleotides to c-myb1 J. Biol. Chem., February 18, 2000; 275(7): 4647 - 4653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Wang, X. Y. Yang, R. A. Kirken, J. H. Resau, and W. L. Farrar Targeted disruption of Stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven TH2 cell response Blood, February 15, 2000; 95(4): 1249 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Tang, D. Mohuczy, Y. C. Zhang, B. Kimura, S. M. Galli, and M. I. Phillips Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2392 - H2399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Makino, M. Sugano, S. Ohtsuka, S. Sawada, and T. Hata Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats Cardiovasc Res, December 1, 1999; 44(3): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nishii, A. Moriguchi, R. Morishita, K. Yamada, S. Nakamura, N. Tomita, Y. Kaneda, A. Fukamizu, H. Mikami, J. Higaki, et al. Angiotensinogen Gene–Activating Elements Regulate Blood Pressure in the Brain Circ. Res., August 6, 1999; 85(3): 257 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Raizada, M. J. Katovich, H. Wang, K. H. Berecek, and C. H. Gelband Is antisense gene therapy a step in the right direction in the control of hypertension? Am J Physiol Heart Circ Physiol, August 1, 1999; 277(2): H423 - H432. [Full Text] [PDF]
|
|
|
|
|
|
S. Tomita, N. Tomita, T. Yamada, L. Zhang, Y. Kaneda, R. Morishita, T. Ogihara, V. J. Dzau, and M. Horiuchi Transcription Factor Decoy to Study the Molecular Mechanism of Negative Regulation of Renin Gene Expression in the Liver In Vivo Circ. Res., May 14, 1999; 84(9): 1059 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Phillips Is Gene Therapy for Hypertension Possible? Hypertension, January 1, 1999; 33(1): 8 - 13. [Full Text] [PDF]
|
|
|
|
|
|
D. Mohuczy, C. H. Gelband, and M. I. Phillips Antisense Inhibition of AT1 Receptor in Vascular Smooth Muscle Cells Using Adeno-Associated Virus-Based Vector Hypertension, January 1, 1999; 33(1): 354 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Morishita, J. Higaki, N. Tomita, and T. Ogihara Application of Transcription Factor "Decoy" Strategy as Means of Gene Therapy and Study of Gene Expression in Cardiovascular Disease Circ. Res., June 1, 1998; 82(10): 1023 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Makino, M. Sugano, S. Ohtsuka, and S. Sawada Intravenous Injection With Antisense Oligodeoxynucleotides Against Angiotensinogen Decreases Blood Pressure in Spontaneously Hypertensive Rats Hypertension, May 1, 1998; 31(5): 1166 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-J. Zhu, M. K. Bagchi, and I. C. Bagchi Attenuation of Calcitonin Gene Expression in Pregnant Rat Uterus Leads to a Block in Embryonic Implantation Endocrinology, January 1, 1998; 139(1): 330 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Corvol and X. Jeunemaitre Molecular Genetics of Human Hypertension: Role of Angiotensinogen Endocr. Rev., October 1, 1997; 18(5): 662 - 677. [Abstract] [Full Text]
|
|
|
|
|
|
D. Lu, M. K. Raizada, S. Iyer, P. Reaves, H. Yang, and M. J. Katovich Losartan Versus Gene Therapy : Chronic Control of High Blood Pressure in Spontaneously Hypertensive Rats Hypertension, September 1, 1997; 30(3): 363 - 370. [Abstract] [Full Text]
|
|
|
|
|
|
M. I. Phillips, D. Mohuczy-Dominiak, M. Coffey, S. M. Galli, B. Kimura, P. Wu, and T. Zelles Prolonged Reduction of High Blood Pressure With an In Vivo, Nonpathogenic, Adeno-Associated Viral Vector Delivery of AT1-R mRNA Antisense Hypertension, January 1, 1997; 29(1): 374 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Dzau and M. Horiuchi In Vivo Gene Transfer and Gene Modulation in Hypertension Research Hypertension, December 1, 1996; 28(6): 1132 - 1137. [Abstract] [Full Text]
|
|
|
|
|
|
M. Sugano and N. Makino Changes in Plasma Lipoprotein Cholesterol Levels by Antisense Oligodeoxynucleotides against Cholesteryl Ester Transfer Protein in Cholesterol-fed Rabbits J. Biol. Chem., August 9, 1996; 271(32): 19080 - 19083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wielbo, A. Simon, M. I. Phillips, and S. Toffolo Inhibition of Hypertension by Peripheral Administration of Antisense Oligodeoxynucleotides Hypertension, July 1, 1996; 28(1): 147 - 151. [Abstract] [Full Text]
|
|
|
|
|
|
K. Tamura, S. Umemura, N. Nyui, T. Yamakawa, S. Yamaguchi, T. Ishigami, S.-i. Tanaka, K. Tanimoto, N. Takagi, H. Sekihara, et al. Tissue-Specific Regulation of Angiotensinogen Gene Expression in Spontaneously Hypertensive Rats Hypertension, June 1, 1996; 27(6): 1216 - 1223. [Abstract] [Full Text]
|
|
|
|
|
|
R. Morishita, J. Higaki, N. Tomita, M. Aoki, A. Moriguchi, K. Tamura, K. Murakami, Y. Kaneda, and T. Ogihara Role of Transcriptional cis-Elements, Angiotensinogen Gene–Activating Elements, of Angiotensinogen Gene in Blood Pressure Regulation Hypertension, March 1, 1996; 27(3): 502 - 507. [Abstract] [Full Text]
|
|
|
|
|
|
M. Schinke, M. Bohm, G. Bricca, D. Ganten, and M. Bader Permanent Inhibition of Angiotensinogen Synthesis by Antisense RNA Expression Hypertension, March 1, 1996; 27(3): 508 - 513. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. K. Askari and W. M. McDonnell Antisense-Oligonucleotide Therapy N. Engl. J. Med., February 1, 1996; 334(5): 316 - 318. [Full Text] [PDF]
|
|